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3194Objective: To conduct a test of noninferiority for CardioCel (Admedus, Brisbane, Australia), a chemically
engineered bovine pericardium over autologous pericardium treated intraoperatively with glutaraldehyde in a
chronic juvenile sheep model of pulmonary valve (PV) and mitral valve (MV) reconstruction.
Methods:We replaced the posterior leaflet of the MVand of 1 PV cusp with patches in ewes aged 10 months.
There were 2 groups: CardioCel (n¼ 6) and control (n¼ 4). All valves were competent. Echocardiography was
performed before euthanasia. The collected data were function, macroscopy, histology, and calcium contents.
The primary end points were thickening and calcium content.
Results: All animals survived until sacrifice after 7 months. The valves had normal echo. The macroscopic
aspect of the valves was excellent. Examination of the slides for both groups revealed a continuous endothelium
on both sides of the patch and a layer of new collagen developed on both sides between patch and endothelium
and interstitial cells and smooth muscle cell in these layers. The patch had not thickened but the 2 layers of new
collagen for the PV showed a median thickening of 37% in the CardioCel group and 111% in the control group
(P ¼ .01), and for the MV a thickening of 108% and 251%, respectively, was seen (P ¼ .01). The median
calcium content in the PV was 0.24 mg/mg (range, 0.19-0.30) in the CardioCel group versus 0.34 mg/mg
(range, 0.24-0.62) in controls (P ¼ .20). In the MV it was 0.46 mg/mg (range, 0.30-1.0) in the CardioCel group
and 0.47 mg/mg (range, 0.29-1.9) in controls (P ¼ 1.0).
Conclusions: In this growing lamb model the CardioCel patch allowed accurate valve repair at both systemic
and pulmonary pressure. The mechanical properties of CardioCel after 7 months were preserved with a more
controlled healing than the treated autologous pericardium and without calcification. (J Thorac Cardiovasc
Surg 2014;148:3194-201)See related commentary on pages 3202-3.
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The Journal of Thoracic and Cardiovascular SurOur department is heavily involved in pediatric valve
repair.1-3 Despite a long history of trial and error and
extensive clinical and experimental research in our unit
and others,4 the ideal material for valve tissue replacement
and extension is yet to be found. As in many units, for more
than 2 decades our best default material for valve repair has
been autologous pericardium treated intraoperatively with
0.625% glutaraldehyde.5
In 2009 we were introduced to CardioCel (Admedus,
Brisbane, Australia), a pericardium patch developed
and chemically engineered in Australia. The multistep
ADAPT treatment ([Admedus] decellularized with Tx-100;
deoxycholate, IgePal CA-630; and denucleased, cross-
linked in 0.05% monomeric glutaraldehyde and detoxified)
applied to bovine pericardium confers to the treated
patch complete fixation,6 fine handling properties, and out-
standing resistance to calcification.6,7
Before committing to use of this novel product for
valve repair in pediatric patients, we reviewed invivo studies
performed in subcutaneous juvenile rat models first against
human pericardium rapidly cross-linked with 0.6% glutar-
aldehyde for 4 minutes and detoxified with magnesiumgery c December 2014
Brizard et al Evolving Technology/Basic Sciencechloride, and with human pericardium exposed to the multi-
stepADAPT treatment.8 Both studies showed the CardioCel
product to have complete cross-linking and extreme resis-
tance to calcification. These characteristicswere far superior
to the ones of the current default materials used in the unit.
The purpose of our study was to compare in a juvenile
sheep model the autologous pericardial patch cross-linked
intraoperatively versus CardioCel in a clinical situation.
Both the pulmonary valve and the mitral valve were
partially replaced with the materials studied. The model has
been used in the past for themitral valve position (Michel Pel-
lerin and Alain Carpentier, personal communication, 2011)
anddiscriminates for themechanical properties and calcifica-
tion of the patch. In our model we added the partial replace-
ment of the pulmonary valve to evaluate the mechanical
properties of CardioCel in the semilunar location.E
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This was a prospective, nonrandomized study performed as a test of
noninferiority of the CardioCel patch to the autologous pericardium
cross-linked in the operating theater with glutaraldehyde 0.625%. Primary
end points were thickening and calcium content. Secondary end points
were echographic evaluation, macroscopic evaluation, histology, and
immunohistochemistry. The 4 animals of the control group received
autologous pericardium patches treated intraoperatively with glutaralde-
hyde. The 6 animals of the study group received CardioCel patches.
The order of the surgeries was as follows: the first 2 animals received
CardioCel, then 1 control, 4 additional animals received CardioCel, and
the 3 final animals were control over a 6-week period.
All animals received humane care in compliance with the Principles of
Laboratory Care (National Society for Medical Research) and the
Guide for the Care and Use of Laboratory Animals. The Animal Ethics
Committee of the University of Melbourne approved the study protocol.
The surgery was performed at the Surgery and Biomaterial Research
Unit in the University of Melbourne Veterinary Hospital, Werribee, and
the animals were kept in the same location afterward.
Surgical Preparation
The animals were anesthetized and prepped according to a previously
published protocol.9 The sheep were premedicated with buprenorphine
(0.01mg/kg) before induction of anesthesia with intravenous propofol
(4 mg/kg). An endotracheal tube was placed and the cuff inflated.
Anesthesia was maintained with a mixture of isoflurane (1.5%-2%) and
oxygen via an anesthetic machine. Fentanyl citrate (0.4 mg/kg/min) was
used while the sheep were on cardiopulmonary bypass. Paralysis was
induced with intravenous atracurium 0.5 mg/kg initially followed by
boluses of 0.1-0.2 mg/kg every hour or as required. The sheep were
mechanically ventilated at 1.5 L/min, 25 cm water pressure 8 bpm, 80 to
100 mL tidal volume. A wide bore stomach tube was placed orally to
evacuate the fluid of the rumen during the procedure to prevent aspiration
of ruminal content. Amiodarone 5 mg/kg was administered to prevent
arrhythmias.
A left thoracotomy in the third intercostal space was performed with
division of the fourth costal cartilage. Cardiopulmonary bypass at 34
was instituted between the descending aorta and the body of the right atrium
cannulated through the right atrial appendage. In the control group, a 43 4
cm pericardial patch was harvested; trimmed of fat; treated with 0.625%
glutaraldehyde for 8 minutes; and rinsed in 3 baths of normal saline, the
last 1 containing magnesium.4 In the CardioCel group, the pericardium
was available from the container and used without rinsing or washing.The Journal of Thoracic and CarUnder crossclamp and using repeated warm blood cardioplegia, the left
atrium was incised parallel to the atrioventricular groove and the mitral
valve was exposed. The posterior leaflet was incised 1 mm inside the
annulus and as much as possible of the body of the posterior leaflet was
removed without compromising the marginal chordae. An ellipsoid patch
was tailored and inserted using running 6-0 polypropylene suture material.
The valve was tested with saline inflation. The left atrium was closed.
Then the antero-left aspect of the main pulmonary artery was incised
longitudinally going deep into the corresponding sinus. Under direct
vision, the antero-left cusp was carefully excised following the hinge
line. The cusp was used as a template for tailoring the pericardial
replacement and including the free edge. The pericardial cusp was secured
with running 5-0 polypropylene suture material. The pulmonary valve was
tested with saline. The pulmonary artery was closed and the heart deaired.
Bypass was terminated when the temperature reached 38C. The chest was
closed on 1 chest drain that was removed several hours after the lamb was
back in its pen. Heparin was given for 24 hours.
Follow-up Protocol
The animals were kept in their pen onsite for the duration of the study.
Five months are required to adhere to the recommendations of ISO
10993-1:2009—Biological evaluation of medical device. Our aim was to
close and complete the study once calcifications were visible on
echocardiography in either group or after 12 months. At 8 months after
the initial procedure, 2 control animals were anesthetized and the left
thoracotomy was reopened. Epicardial echocardiography was performed
and enhanced echogenicity of the mitral patch was seen in both animals
(Figure 1, A). The decision was made to put to death all animals with
2 CardioCel animals also having a general anesthesia induction and an
epicardial echocardiographic study, whereas the other animals were put
to death with a lethal injection of phenobarbital.
Macroscopic Examination, Histology, and Calcium
Analyses
The hearts were explanted and the valves were dissected out en bloc.
The macroscopic aspect and pliability of the valves and the patches were
evaluated. The valves were labelled and photographed. The valves were
then fixed in 10% buffered formalin and stored in that solution. The tissues
were included in paraffin and 0.5-mm sections prepared for histology stains
that included hematoxylin and eosin, trichrome, Von Kossa, and picrosirius
red. Immunohistochemistry was performed in both groups on some
histology sections and included Factor VIII, smooth muscle actin, and
vimentin. The pathologist who reviewed the slides was blinded to the
groups. The thickening above and below the patch was calculated after
measuring the total area of thickening over a specific length and expressed
in micrometers (micrometers squared thickening divided by micrometer
length of valve tissue). The thickening was reported to the thickness of
the patch as measured on the slide and expressed in percent of the later. Cal-
cium content was measured by an independent assessor by means of induc-
tively coupled plasma mass spectrometry using a Varian Vista atomic
emission spectrometer with axial viewing and a continuing calibration
blank (Varian Australia Pty Ltd, Victoria, Australia).
Precise limited and identical area or the valves were used for
histology section, whereas the remaining tissue was used for calcium
content measurement. Calcium content was also measured in samples of
surrounding native valve tissue of the host animal.
Statistical Analysis
Prism software version 5.0 (exact graphs and data analysis) statistical
package for windows (GraphPad Software, La Jolla, Calif) and Stata
12 (Statcorp, College Station, Tex) were used for statistical analysis. Quan-
titative data were presented as median and range. Nonparametric c2 test of
medians was used to compare CardioCel and control groups, with results
cross-checked against the more conservative Fisher exact test. Mediandiovascular Surgery c Volume 148, Number 6 3195
FIGURE 1. Epicardial echocardiography. A, Long axis study of the mitral valve. Thewhite arrow points at the posterior leaflet bearing the hyperechogenic
autologous pericardial patch. B, Long axis study of the mitral valve. The white arrow points at the posterior leaflet that does not display hyperechogenicity.
C, Long axis of the pulmonary valve. The white arrow points at the unremarkable autologous patch. D, Short axis of the pulmonary valve. The white arrow
points at the CardioCel patch, thin and flexible.
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using a nonparametric matched-pairs sign test.
RESULTS
Ten Corriedale Merino ewes (aged 10 months), median
weight 32.5 kg (range, 27.5-40 kg), were operated on. All
animals survived without complications.
Epicardial Echocardiographic Studies
Two control animals (out of 4) and 2 study animals
(out of 6) underwent epicardial echocardiography after
dissection of the adherences under general anesthesia.
In the 2 control animals, the echocardiographic study
demonstrated enhanced echogenicity with shadowing in
both mitral valve patches and on 1 pulmonary valve patch.
One pulmonary valve had trivial regurgitation. In the study
group, both animals were free of calcification on both sites.
In both groups, the echocardiographic aspect was of thin
and pliable patches (Figure 1, A-D).
Macroscopic Examination
In all animals and in both locations, the surface of the
patches was smooth and without evidence of macroscopic
thrombi attached or visible calcification. The aspect was
very satisfactory. There was no sign of retraction or dilation
and no perforation was detectable (Figure 2, A-D).
Slides
In all groups and in both sites, 3 layers could be distinctly
identifiedusing conventional stain and immunohistochemistry.3196 The Journal of Thoracic and Cardiovascular SurIn all patches, 2 outer layers made of organized collagen
and containing very few cells were covering each side of the
pericardial patch, representing the middle layer. Hematoxylin
and eosin slides are shown in Figure 3, A-D. In both groups,
a continuous endothelial lining was visible on the external
blood interface and confirmed with Factor VIII presence
(Figure 4, A-D).
Picrosirius red stains collagen I (fibers) in deep yellow
and red birefringence, whereas collagen III (fibrils),
which are less mature and less organized, display green
birefringence.10
The slides of the control group mitral valves showed
a high density of collagen I in the native patch in the middle
layer, whereas the outer layers were twice as thick and very
loose with a low density of collagen I. Low intensity green
staining is visible in either layer (Figure 5, A).
The mitral valves in the CardioCel group patches show a
high density of collagen I in the patch and in the outer layers.
However, the outer layers are thin and regular, half the thick-
ness of the patch itself. Collagen III is visible in the patch and
to a lesser degree in the outer layers (Figure 5, B).
The pulmonary valves slides show a similar pattern with
a very thin layer of predominantly collagen I laid on each
side of the patch for the CardioCel group, whereas the
control group patches were deeply imbedded between
thick layers of collagen I and III. The overall thickness
of the control group patches, including the superior and
inferior layers, were twice the thickness of the CardioCel
patch (Figure 5, C and D).gery c December 2014
FIGURE 2. Macroscopy. A and B, both the autologous and the CardioCel patches have the samemacroscopic aspect. C and D, Both the autologous and the
CardioCel are flexible. The CardioCel patch after 8 months implantation is remarkably comparable to a fresh patch.
Brizard et al Evolving Technology/Basic ScienceIn all groups, few neocapillaries, valve interstitial cells
(myofibroblasts), some monocytes, and cells with smooth
muscle cells phenotype (confirmed with smooth muscle a
actin stain; photo not shown) were visible. Trichrome stain
is shown in Figure 6, A-D.FIGURE 3. Hematoxylin and eosin. A, B, C, and D, All slides show a cent
An endothelial layer is continuous on the outer surface of the new collagen la
autologous group mostly the mitral slide (A).
The Journal of Thoracic and CarIn the control group only, rare calcifications were seen
using Von Kossa stain (photo not shown). However, only
part of the patches in both group were available for section
and staining, the remaining having been kept for the cal-
cium measurements.ral layer made of the original patch and 2 outer layers of new collagen.
yers. Some mononucleated cells and lymphocytes can be identified in the
diovascular Surgery c Volume 148, Number 6 3197
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FIGURE 4. Factor VIII immunohistochemistry. A, B, C, and D, The presence of a continuous endothelium in all groups on the outer margin of the
neocollagen layers.
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The thickness of the explanted patches was compared
with the thickness at the time of implantation. The Cardio-
Cel patches were 0.4 mm thick at the time of implantationFIGURE 5. Picrosirius red. In the control group ([A] mitral and [C] pulmonary)
same thickness than the central layer (autologous pericardial patch). The outer la
ture collagen III in green. In the CardioCel (Admedus, Brisbane, Australia) grou
made exclusively of collagen I.
3198 The Journal of Thoracic and Cardiovascular Sur(manufacturer’s specification). The thickness was identical
on the explanted CardioCel patches measured on the
slides (median 0.398 mm and 0.389 mm) in the mitral
and pulmonary valve positions, respectively (Table 1).the outer layers are made of new collagen, predominantly collagen I, of the
yers are much less dense than the autologous patch and contain some imma-
p ([B] mitral and [D] pulmonary, the outer layers are very dense but thin and
gery c December 2014
FIGURE 6. Trichrome staining with differential color adjustment demonstrating endothelial cells on the surface followed by a mixture of smooth
muscle cells (confirmed by the smooth muscle cell a actin immunohistochemistry; photo not shown) and interstitial cells in the newly formed collagen.
A and C, Control groups. B and D, CardioCel (Admedus, Brisbane, Australia). Note the difference in the distribution of the cells between groups.
(High contrast light microscopy with; original magnification 3 100).
Brizard et al Evolving Technology/Basic ScienceThe autologous pericardial patch thickness at the time of
explantation was measured on the slides—median 0.206
mm and 0.159 mm for mitral and pulmonary patches,
respectively—but the thickness at the time of implantation
could not be measured. As found in the CardioCel group, it
was assumed that the patch itself in the control group had
not thickened.
Thickening
The thickness of the superior and inferior layers of new
collagen (the thickening) was measured. The combined
thickness of the superior and inferior layers of new collagen
was reported to the thickness of the patch at the time of
explantation for both positions and both groups (Table 1)
and expressed in percent of the latter. For the pulmonary
valves the median thickening was 37% in the CardioCel
group and 111% in the control group (P ¼ .01). For the
mitral valves the median thickening was 108% in the Car-
dioCel group and 251% in the control group (P ¼ .01).TABLE 1. Thickness and thickening
Group (N ¼ 20) Mitral control (n ¼ 4) Mitral CardioCe
Initial patch thickness (mm) NA 0.4
Patch thickness on the slide (mm) 0.206 (0.17-0.3) 0.398 (0.3-0
Thickness of new collagen (mm) 0.55 (0.36-0.63) 0.43 (0.2-0
Thickening ratio (%) 251 (162-286) 108 (50-1
P .01*
Values are given as median (range) unless otherwise noted. NA, Not applicable. *Fisher
Australia). yFisher exact test P ¼ .048 for pulmonary control versus pulmonary CardioCe
The Journal of Thoracic and CarExtractable Calcium Contents
The median calcium content in the pulmonary valves was
0.34 mg/mg (range, 0.24-0.62 mg/mg) of dry tissue in
the control group versus 0.24 mg/mg (range, 0.19-0.30
mg/mg) in the CardioCel group (P ¼ .20) (Tables 2 and 3).
In the mitral valves the median calcium content was 0.47
mg/mg (range, 0.29-1.9 mg/mg) in the control group and
0.46 mg/mg (range, 0.30-1.0 mg/mg) in the CardioCel
group (P ¼ 1.0). The median calcium content of the
valvular tissue surrounding the repair was higher in all
groups compared with the calcium content of the patches
themselves. The difference was more pronounced in the
CardioCel pulmonary valves (median, 0.87 vs 0.24;P¼ .03).
DISCUSSION
Interpretation of the Data
The purpose of our study was to evaluate the behavior of
the patch over the long-term; the testing of the cross-linking
having been conducted and published before.6 Tensilel (n ¼ 6) Pulmonary control (n ¼ 6) Pulmonary CardioCel (n ¼ 6)
NA 0.4*
.49) 0.159 (0.12-0.31) 0.389 (0.31-0.45)
.56) 0.24 (0.12-0.66) 0.15 (0.12-0.24)
39) 111 (53-297) 38 (31-59)
.01y
exact test P ¼ .048 for mitral control versus mitral CardioCel (Admedus, Brisbane,
l.
diovascular Surgery c Volume 148, Number 6 3199
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TABLE 2. Calcium content in the mitral valve patches and surrounding valve tissue
Group Mitral control (n ¼ 4) Mitral CardioCel (n ¼ 6) Mitral surrounding control (n ¼ 4)
Mitral surrounding
CardioCel (n ¼ 6)
Calcium (mg/mg) 0.47 (0.29-1.87) 0.46 (0.3-1.0) 0.63 (0.58-0.71) 0.62 (0.35-0.77)
P 1*
Values are given as median (range). *Mitral CardioCel (Admedus, Brisbane, Australia) versus control.
Evolving Technology/Basic Science Brizard et al
E
T
/B
Sproperties were determined by an independent assessor
(study report No. 061210R1, Helm-Holtz Institute, Aachen,
Germany). Acute resistance to systemic pressure (ultimate
strength) of the CardioCel patch has been compared with
the ultimate strength of the human aorta and aortic valve
cusp. The ultimate strength in 11 CardioCel samples was
9.18  0.54 N/mm2, exceeding the longitudinal ultimate
tensile strength of the normal human ascending aorta
(1.8  0.24 N/mm2)11 and the circumferential ultimate
tensile strength of the normal human aortic cusp
(1.71 0.14 N/mm2)12 by a magnitude of more than 5-fold.
In our study, both patches behave very satisfactorily at the
8 months horizon. All mitral valves were competent and 1
pulmonary valve had trivial incompetence in the control
group. Both patches demonstrated healing, lining each
side with a layer of new collagen covered with continuous
endothelial cells. The composition of the layer of
new collagen varied between the control group and the
CardioCel group. The collagen I was thin and dense in
the CardioCel group. In the control group the collagen I
was thick and less dense in the pulmonary position and
even less so in the mitral position. Hardly any collagen III
was visible in the CardioCel group, whereas some was
visible in the control group both in the patch and in the outer
layers. The picrosirius red slides suggest that in the control
group a low-grade remodeling process with production of
collagen III was occurring in the native patch while the
healing process in the outer layers was still active. In the
CardioCel group, the picrosirius red suggests that the
healing process was controlled and completed with thin
and organized dense collagen I and hardly any collagen III.
There were very low calcium concentrations in both
groups, confirming the resistance to calcification of the auto-
logous pericardium treated extemporarily. However, there
was superior resistance to calcification in the CardioCel
patch, particularly in the pulmonary position. The calcium
level in the native tissue valve surrounding the patch was
consistently higher than in the patch in both groups, with
the difference more pronounced in the CardioCel studyTABLE 3. Calcium content in the pulmonary valve patches and surround
Group Pulmonary control (n ¼ 4) Pulmonary CardioC
Calcium (mg/mg) 0.34 (0.24-0.62) 0.24 (0.19-0.
P* .2y
Values are given as median (range). *c2 rank sum test of median. yPulmonary CardioCel
3200 The Journal of Thoracic and Cardiovascular Surgroup. This finding confirms the resistance to calcification,
and also signifies that the patches host essentially too few
cells to demonstrate evidence of calcium metabolism.
The minimal calcification level and the absence of lym-
phocytes together with the quality of the healing process sug-
gest a mild and insignificant immune response by the host to
the patch.13 Both are less with the bovine pericardium treated
with ADAPT then with the conventional intraoperative treat-
ment of the autologous pericardium, confirming in thismodel
the findings of the subcutaneous implantation in rats.6,8
COMMENTS
The aim of our study was first to evaluate the CardioCel
patch in the valvular setting at systemic and pulmonary pres-
sure and second to compare it with the default state-of-the-
art material for pediatric valve repairs. We deliberately used
for control autologous pericardia treated intraoperatively
with glutaraldehyde instead of other commercially available
regular bovine pericardia. As demonstrated with our own
subcutaneous model in rats and by others,8 a standard
glutaraldehyde-treated bovine pericardium patch performs
much less satisfactorily than the intraoperatively treated autol-
ogous pericardium. This has also been demonstrated in human
clinical practice in our center andbyothers.14 Inourpractice as
in many other units, use of standard commercially available
treated bovine pericardia was abandoned many years ago.
We do not use untreated autologous pericardium apart
from the pulmonary sinus reconstruction in arterial
switch.15 Despite unfavorable experimental data suggesting
retraction and thickening,16 some units use it routinely for
aortic valve repair.17
Therefore, we used for control the material currently
most apt for valve repair in pediatric patients and indeed
the 1 less likely to be inferior to the CardioCel patch.
The end points of our study were clinical (ie, function of
the valve, histology, inflammation, and evidence of host
response) and chemical (ie, calcification level).
Despite the complexity of the model, perfect initial
outcome was achieved with both materials. All animalsing valve tissue
el (n ¼ 6)
Pulmonary surrounding
control (n ¼ 4)
Pulmonary surrounding
CardioCel (n ¼ 6)
3) 0.9 (0.3-2.53) 0.87 (0.62-0.92)
.03z
(Admedus, Brisbane, Australia) versus control. zCardioCel versus surrounding.
gery c December 2014
Brizard et al Evolving Technology/Basic Sciencesurvived to the term of the study. Both materials performed
to the expected outcome result with competent valves and
normal echocardiographic function of the patch in the
animals tested. This demonstrates the noninferiority of the
CardioCel patch for the clinical end points during the
time span studied. As for the microscopic- and calcium-
level primary end points, the CardioCel patch has
significantly improved results for thickening and less
calcification in the pulmonary position. Calcification is
equivalent in the mitral position with a smaller standard
deviation. In both sites, the calcium level is significantly
less than in the surrounding tissue. The histologic studies
demonstrate that CardioCel generates a more controlled
and gentle healing process despite a greater collagen mass
(as suggested by the initial patch thickness) than in the
autologous pericardium in this infant lamb model.CONCLUSIONS
In this rare, long-term animal model, CardioCel
compared very favorably to state-of-the-art autologous
pericardium treated intraoperatively with glutaraldehyde
in terms of valve function, both in the systemic and
pulmonary pressure regimen. A controlled, low-grade,
and harmonious healing process was demonstrated. The
patch is associated with extremely low calcium deposition,
lower than in the control autologous pericardium in the
pulmonary position. These findings suggest that the very
long-term mechanical properties of the patch should be
preserved in clinical situations.References
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